2,731 participants from 26 brazilian states and also from other countries, watched, during 4 days, the virtual scientific program. The event was attended by renowned speakers that presented the main studies of ASCO 2020 on different  research fields (Genitourinary, Melanoma/Sarcoma, Gastrointestinal, Hematologic, Breast, Gynecological, Lung, Head and Neck and Neuro), in addition to discussing the perspective of clinical practice. We thank all the attendees, speakers, supporters and sponsors for having been a part of this great event.    The Best of ASCO 2020 Brazil Edition, organized by LACOG and Ética Institute, is an event officially licensed by ASCO, which organizes the most important oncology congress in the world with a commitment to accelerating progress against cancer, even in the face of a global pandemic.

It is with great pleasure that we present the first edition of the LACOG Annual Report, which highlights the most important activities of our group during the year of 2019. Check the 2019 annual report

Although the COVID-19 pandemic has prevented on-site attendance at this year’s ASCO meeting (May 29th – May 31st), the global oncology community presented a large range of relevant and potentially practice-changing findings. Highlights of this report include the progress made with regard to various aberrations like ALK, MET, HER2 and RET alterations, as well as EGFR exon 20 insertions and promising drugs in this difficult-to-treat subtype. Moreover, topics including (neo)adjuvant approaches for early stage NSCLC, future perspectives of anti-angiogenic therapy and COVID-19 in the context of thoracic cancer care are covered. Furthermore, the importance of immune checkpoint inhibitors and the determination of unequivocally active combinations of immune agents are addressed. Last but not least, advances in the field of SCLC treatment are presented, valuing immunotherapy in addition to platinum-based chemotherapy, thus bearing a possible new standard-of-care treatment for first-line ES-SCLC. As an additional feature, you will find expert video interviews with Victor Moreno and Helmut Prosch on different conference highlights on memo inOncology website. The memo inOncology Special Issue report is produced by Springer, as a supplement of memo (the Magazine of European Medical Oncology) and sponsored by Boehringer Ingelheim with an unrestricted educational grant. For more information on the memo inOncology

This month was handed to AMO Clinic (located in Salvador, Brazil) the CURA Recognition Award. AMO is the first institution to receive it, as they have supported CURA since 2015. Learn about CURA Project and get in contact to know how you can effectively be part of CURA Partners. Picture: Dr. Alex Pimenta (Medical Director) and Dr. Carlos Sampaio (president of the administrative council).

Have you already subscribed to the Best of SABCS Brazil edition? The Best of SABCS® official highlights programs that allow professionals the opportunity to experience and discuss the most current researches and advances in the field of breast cancer, with colleagues and key opinion leaders. The Brazilian edition is going to be held by LACOG and GBECAM, on March 27th and 28th, 2020, at the Intercontinental Hotel, in São Paulo. For more information, access: https://lnkd.in/dfhAQYe

Dr. Tomas Reinert presents a poster at San Antonio Breast Cancer Symposium 2019, US, showing that ESR1 mutations are not a mechanism of primary resistance to aromatase inhibitors in ER-positive breast cancer treated with neoadjuvant endocrine therapy. The study was part of his Ph.D. thesis at the Universidade Federal do Rio Grande do Sul in collaboration with several other institutions including LACOG.